默沙东 2020年4月30日讯 /生物谷BIOON/ --默沙东(Merck & Co)近日宣布,美国食品和药物管理局(FDA)已批准抗PD-1疗法Keytruda(可瑞达,通用名:pembrolizumab,帕博利珠单抗)一个新的给药方案——每6周一次400毫克(400mg Q6W),用于所有已批准的成人适应症,包括单药治疗和联合治疗。该方案具体为:每6周 2020年4月...
KEYTRUDA is indicated for use at an additional recommended dosage of 400 mg every 6 weeks for classical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma in adults [see INDICATIONS AND USAGE, DOSAGE AND ADMINISTRATION]. This indication is approved under accelerated approval based on phar...
In adults,Keytruda is usually given every 3 weeks or 6 weeksdepending on the dose that you are receiving. In children, Keytruda is usually given every 3 weeks. Your healthcare provider will decide how many treatments you need. Your healthcare provider will do blood tests to check you for ...
investigatedinTrial6.Trial6wasamulticenter,open-label,active-controlledtrialwherepatientswere randomized(1:1:1)andreceivedKEYTRUDA10mg/kgevery2weeks(n=278)orKEYTRUDA10mg/kg every3weeks(n=277)untildiseaseprogressionorunacceptabletoxicityoripilimumab3mg/kgevery 3weeksfor4dosesunlessdisearlierfordiseaseprogression...
Adult individuals with HER2-positive gastric cancer: 200 mg every 3 weeks or 400 mg every 6 weeks; administer Keytruda prior to trastuzumab and chemotherapy when given on the same day; until disease progression, unacceptable toxicity, or up to 24 months ...
It is given as directed by your doctor, usually once every 3 weeks or once every 6 weeks. The dosage is based on your medical condition and response to treatment. Children's dosage is also based on weight. Infusion reactions may happen during the infusion of this drug. Tell your doctor...
mg/kg (up to a maximum of 200 mg) every three weeks until disease progression or unacceptable toxicity, or up to 24 months in patients without disease progression. Urothelial Carcinoma KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic uroth...
In KEYNOTE-051, 173 pediatric patients (65 pediatric patients aged 6 months to younger than 12 years and 108 pediatric patients aged 12 years to 17 years) were administered KEYTRUDA 2 mg/kg every 3 weeks. The median duration of exposure was 2.1 months (range: 1 day to 25 months...
In KEYNOTE-051, 173 pediatric patients (65 pediatric patients aged 6 months to younger than 12 years and 108 pediatric patients aged 12 years to 17 years) were administered KEYTRUDA 2 mg/kg every 3 weeks. The median duration of exposure was 2.1 m...
(1.1, 1.2) - DOSAGE AND ADMINISTRATION - Administer 2 mg/kg as an intravenous infusion over 30 minutes every 3 weeks. (2.2) Dilute prior to intravenous infusion. (2.4) -DOSAGE FORMS AND STRENGTHS - For injection: 50 mg lyophilized powder in single-use vial for reconstitution (3) ...